Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“New biomarker insight in 1L NSCLC
A prospective analysis from CHOICE-01 shows that tumor-informed ctDNA may finally give us the predictive tool we’ve been missing for selecting pts for ICI + chemo.
Key findings:
- ctDNA-positive pts had major benefit from ICI-chemo vs chemo alone
• PFS HR 0.45
• OS HR 0.66 - ctDNA-negative pts → no significant difference between arms
- Predictive value independent of PD-L1 and other immune biomarkers
- Validated in combined RATIONALE 304/307 cohort
- On-treatment ctDNA clearance linked to improved OS and PFS
ctDNA is emerging as a powerful tool to refine immunotherapy selection and early response assessment.”
More posts featuring Aakash Desai.
